Active, not recruitingPhase 2NCT04166318
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Studying Carcinoma of the anal canal
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Principal Investigator
- Jennifer A DorthECOG-ACRIN Cancer Research Group
- Intervention
- Biopsy(procedure)
- Enrollment
- 252 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2029
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
- Alaska Women's Cancer Care, Anchorage, Alaska, United States
- Anchorage Oncology Centre, Anchorage, Alaska, United States
- Katmai Oncology Group, Anchorage, Alaska, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
- Kingman Regional Medical Center, Kingman, Arizona, United States
- Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
- Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
- CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04166318 on ClinicalTrials.govOther trials for Carcinoma of the anal canal
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07029152Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure ProphylaxisUniversitair Ziekenhuis Brussel
- ACTIVE NOT RECRUITINGPHASE3NCT06866574A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese MalesXiamen University
- RECRUITINGPHASE2NCT06640283Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical OutcomesInstituto do Cancer do Estado de São Paulo
- RECRUITINGNANCT06792604Host Genome Methylation: a Screening Tool in Anal Cancer DetectionAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE3NCT06207981Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCAFederation Francophone de Cancerologie Digestive
- RECRUITINGPHASE2NCT05661188Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)Grupo Espanol Multidisciplinario del Cancer Digestivo
- RECRUITINGNCT06327568Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal SpecimensEuropean Institute of Oncology
- RECRUITINGNCT05438836Re-optimization Based Online Adaptive Radiotherapy of Anal CancerHerlev Hospital